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Abstract
 
Interleukin (IL)-12 may be secreted as a bioactive T helper type 1 (Th1) cell–inducing het-
erodimer, as a monomer, or as an antagonistic homodimer. We analyzed the IL-12 produced
by mouse splenic dendritic cells (DCs), human thymic DCs, and cultured human monocyte-
derived DCs. IL-12 production required both a microbial or T cell–derived stimulus and an
appropriate cytokine milieu. The different IL-12 forms were differentially regulated by the cy-
tokines present rather than the stimulus used. IL-4 alone or together with granulocyte/mac-
 
rophage colony-stimulating factor or interferon 
 
g
 
 effectively enhanced the production of the
bioactive heterodimer and selectively reduced the antagonistic homodimer of IL-12. There-
fore, IL-4, the major Th2-driving cytokine, provides a negative feedback causing DCs to pro-
duce the major Th1-inducing cytokine, bioactive IL-12.
 
Key words: granulocyte/macrophage colony-stimulating factor • homodimeric interleukin 12 • 
 
T helper type 1 • T helper type 2 • interferon 
 
g
 
Introduction
 
IL-12 is a cytokine composed of two disulfide-linked sub-
units of 35 kD (p35) and 40 kD (p40), which are encoded
by two separate genes. These associate to form the bioac-
tive heterodimer of 70 kD (p70 [1–3]). IL-12 p70 acts on T
cells and NK cells by inducing proliferation, enhancing cy-
totoxicity, and promoting IFN-
 
g
 
 production. It is the most
important cytokine for induction of Th1 cells and plays a
major role in resistance to bacterial, viral, and parasitic in-
fections, as well as to tumors (4). Furthermore, as an in-
flammation-promoting cytokine, IL-12 is considered to be
involved in the onset or progress of various autoimmune
diseases (5).
Besides the biologically active heterodimer p70, IL-12
can also be secreted in vitro and in vivo in large excess as a
p40 monomer or (p40)2 homodimer (6, 7). In both mice
and humans, (p40)2 was shown to bind to the IL-12 recep-
tor and antagonize p70-induced T cell proliferation and
IFN-
 
g
 
 production of NK and T cells (8–10). In addition,
recombinant (p40)2 was able to ameliorate IL-12–depen-
dent effects in autoimmune diabetes, endotoxin-induced
shock, and rejection after transplantation (7, 11–13). Simi-
larly, expression of the IL-12 p40 gene in vivo led to pro-
 
longed syngeneic islet graft survival and impaired Th1
responses (14–16). Interestingly, the growth of certain hy-
bridomas in vivo was accompanied by elevated levels of
(p40)2 secretion and suppression of natural immunity (17).
Thus, the biological activity of IL-12 may ultimately be de-
termined by the ratio of p70 to (p40)2, as well as by the ab-
solute levels of the p70 form.
Many APCs produce some IL-12, but dendritic cells
 
(DCs)
 
1
 
 have been shown to be major producers, and their
intimate contact with T cells during initiation of a primary
immune response implicates them as major inducers of Th1
versus Th2 polarization (18, 19). The control of DC IL-12
production is therefore of importance in immune system
regulation. DCs must develop to a certain stage before they
are capable of IL-12 production. The actual production of
IL-12 is highly dependent on both an IL-12 stimulus and
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the cytokine milieu during stimulation. In DCs, the major
stimuli for IL-12 production are of microbiological origin
or are T cell derived, in the latter case mainly the CD40–
CD40 ligand (CD40L) interaction (19–22). Of the cyto-
kines, IFN-
 
g
 
 and GM-CSF are described as enhancers of
IL-12 production, whereas IL-10, prostaglandins, and trans-
forming growth factor 
 
b
 
 are described as potent inhibitors
of IL-12 production (20, 23–26). The role of IL-4 is less
clear, since it is reported to have a positive priming effect
on monocytes if used at least 1 d before the stimulation for
IL-12 production (26–28), but if added simultaneously
with the IL-12 stimulus, then IL-4 is reported to be inhibi-
tory (20, 26, 27, 29–31). Also, one report suggests that IL-
4, if used together with CD40L, has an enhancing effect on
IL-12 production, but if used together with LPS and IFN-
 
g
 
,
has an inhibiting effect (32). Not all of these reports consid-
ered the balance between the various IL-12 forms, and
most used macrophages, blood monocytes, or culture-
derived DCs. In addition, a role for IL-4 in priming or ma-
turing DCs was not always separated from a role in the ac-
tual induction of IL-12 secretion.
In this study we have analyzed the IL-12 p40, p70, and
(p40)2 production of freshly isolated and cultured mouse
and human DCs in rapid response to various stimuli and
under the influence of the cytokines IL-4, GM-CSF, and
IFN-
 
g
 
. To our surprise, IL-4 inhibited the antagonistic
(p40)2 form but increased the bioactive p70 form of IL-12.
By contrast, IFN-
 
g
 
 alone predominantly increased the an-
tagonistic (p40)2 form. Furthermore, IL-4 and IFN-
 
g
 
 to-
gether showed a strong synergism in increasing p70, while
maintaining the IL-4 block of production of the antagonis-
tic (p40)2. Overall, this resulted in an optimal production
of agonist p70 with minimal antagonist (p40)2. These ef-
fects of IL-4 and IFN-
 
g
 
 were observed with a large variety
of microbiological or T cell–dependent stimuli in both
mouse and human DCs, freshly isolated or cultured. This
form of regulation leads to a multiple negative feedback
model with DCs opposing the tendency towards T cell cy-
tokine polarization.
 
Materials and Methods
 
Mice.
 
C57BL/6J wehi mice were bred under specific patho-
gen-free conditions in the animal facility of The Walter and Eliza
Hall Institute.
 
Cytokines, Abs, and Reagents.
 
Murine rGM-CSF, murine rIL-4,
human rGM-CSF, and human trimeric CD40L were gifts from
Immunex Corporation (Seattle, WA). Human rIL-4 (used for
the monocyte-derived DC [MoDC] experiments) was provided
by Schering-Plough Research Institute (Kenilworth, NJ). Rat
rIFN-
 
g
 
 (bioactive in mice), human rIFN-
 
g
 
, and human rIL-4
(used for the human thymic DC experiments) were purchased
from PeproTech. Human rIL-12 p70 and human rIL-12 p40
were purchased from BD PharMingen. Murine rIL-12 p70 and
murine rIL-12 (p40)2 were purchased from R&D Systems. LPS
and polyinosinic-polycytidylic acid (poly I:C) were purchased
from Sigma-Aldrich. Flt3 ligand (Flt3-L) was produced in this
laboratory from the CHO-flk2 cell line provided by Prof. Nic
Nicola (The Walter and Eliza Hall Institute). Pansorbin (fixed
 
and heat-killed 
 
Staphylococcus aureus
 
 Cowan I [SAC]) was pur-
chased from Calbiochem-Novabiochem. An oligonucleotide
containing a CpG motif (CpG) was synthesized by GeneWorks
according to a published sequence (CpG1668 [33]). The hybrid-
oma producing the mAb for human CD40 (G28.5) was ob-
tained from the American Type Culture Collection. The hybrid-
oma producing the mAb for mouse CD40 (FGK45.5) was
provided by Dr. A. Rolink (Basel Institute for Immunology,
Basel, Switzerland). The hybridoma producing a neutralizing
mAb for mouse IL-4 (BVD4-1D11) was provided by Dr. J.
Abrams (DNAX Research Institute, Palo Alto, CA). The fluores-
cence-conjugated Ab used for selecting DCs was FITC-conju-
gated anti-CD11c (N418). mAbs were purified and labeled as
published elsewhere (34, 35).
 
Mouse DC Preparation.
 
Pools of spleens were used for DC
extraction as described in detail elsewhere (34). In brief, organs
were chopped, digested with collagenase, and treated with
EDTA. Light density cells were collected by a density centrifuga-
tion procedure. Non-DC lineage cells were depleted by coating
them with a mixture of mAbs and then depleting the coated cells
with magnetic beads coupled to anti–rat IgG (35). The DC-
enriched preparations were then immunofluorescent stained with
an anti-CD11c–FITC mAb. Propidium iodide was added in the
final wash to label dead cells. For cytometric sorting, the cells
were gated for DC characteristics, namely high forward and side
scatter and bright staining for CD11c, with propidium iodide–
labeled cells excluded. The purity of the sorted DCs was 
 
.
 
98%.
 
Stimulation of Isolated Mouse DCs for IL-12 Production.
 
Sorted
splenic mouse DCs (10
 
5
 
) were cultured in 96-well round-bot-
tomed plates in a final volume of 200 
 
m
 
l with an IL-12 stimulus
(1 
 
m
 
g/ml LPS, 25 
 
m
 
g/ml anti-CD40 mAb, 10 
 
m
 
g/ml poly I:C,
250 nM CpG, 5–20 
 
m
 
g/ml SAC, or mixes containing all stimuli
listed) in the presence or absence of IL-4 (100 U/ml or titrated),
GM-CSF (200 U/ml or titrated), and IFN-
 
g
 
 (20 ng/ml or ti-
trated). After an 18–23-h culture the supernatant was collected,
separated from cells by centrifugation, and stored until analysis at
 
2
 
70
 
8
 
C.
 
Stimulation of Mice for IL-12 Production In Vivo.
 
Mice were
administered LPS (10 
 
m
 
g) or CpG (10 nmol) with or without the
addition of IL-4 (0.5 
 
m
 
g) via intraperitoneal injection. These re-
agents were administered in PBS containing 1% FCS. Control
mice received intraperitoneal injections of PBS/FCS alone. Mice
were killed after 4 h, blood was taken, and the serum was col-
lected for IL-12 assay by ELISA.
 
Generation of Human MoDCs.
 
For MoDC generation, CD14
 
1
 
monocytes were affinity purified using the MACS CD14 iso-
lation kit (Miltenyi Biotec) and 5 
 
3
 
 10
 
5
 
 cells were cultured in
1 ml RPMI 1640, 10% FCS, rGM-CSF (40 ng/ml), and rIL-4
(500 U/ml) in 24-well flat-bottomed plates. By day 7, when
MoDCs represented 
 
.
 
90% of cultured cells, the wells were
pooled and cells were washed extensively to eliminate any IL-4
carryover. These MoDCs would be classed as relatively immature,
expressing only moderate levels of HLA-DR and HLA-A, -B, or
-C, only low levels of CD86, and no detectable CD80 or CD83.
 
Stimulation of Human MoDCs for IL-12 Production.
 
Washed
MoDCs (10
 
4
 
 or 10
 
5
 
 per 200 
 
m
 
l) were plated with CD40L (1 
 
m
 
g/
ml) or a mix of stimuli (1 
 
m
 
g/ml LPS, 25 
 
m
 
g/ml anti-CD40
mAb, 100 
 
m
 
g/ml poly I:C, 1 
 
m
 
M CpG) and the cytokines (10
ng/ml rIL-4, 50 ng/ml rGM-CSF, 20 ng/ml rIFN-
 
g
 
 as specified
in the figure legends) and cultured for 1 or 3 d. The cell-free su-
pernatants were stored until analysis at 
 
2
 
70
 
8
 
C.
 
Isolation of Human Thymic DCs.
 
Human thymus samples
were discarded tissue from newborn children undergoing correc- 
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tive cardiac surgery. The isolation protocol was similar to the
protocol used for mouse DCs. In brief, the tissue was cut into
small fragments, suspended in 10 ml of RPMI 1640 containing
2% FCS, collagenase, and DNase, then digested with intermittent
agitation for 15 min at 37
 
8
 
C followed by 5 min at room temper-
ature with constant agitation. To disrupt DC–T cell complexes,
EDTA was added to the digest, and incubation with agitation was
continued for 5 min. The suspension was then passed through a
stainless steel sieve to remove aggregates. All remaining proce-
dures were performed at 0–4
 
8
 
C. The cells were recovered from
the digest by centrifugation, then the pellet was immediately re-
suspended in 1.068 g/cm
 
3
 
 isoosmotic Nycodenz medium (Ny-
comed Pharma), and a low density fraction was collected after
centrifugation at 1,700 
 
g
 
 for 10 min. The low density fraction
was diluted in balanced salt solution (BSS) containing EDTA, and
the cells were recovered by centrifugation. The cells were then
incubated for 25 min with a mixture of mAbs (all from American
Type Culture Collection) including anti-CD3 (OKT3), anti-
CD8 (OKT8), anti-CD7 (3A1), anti-CD15 (WEMG1), anti-
CD19 (FMC-63), anti-CD20 (B1), and anti–glycophorin A
(10F7MN), in EDTA-BSS containing 2% human serum. After
incubation, the cells coated with mAbs were removed by two cy-
cles of sheep anti–mouse Ig-coupled magnetic beads (Dynabeads;
Dynal). The first cycle was at 3:1 and the second at 6:1 bead to
cell ratio. The cells were then kept overnight at 4
 
8
 
C in EDTA-
BSS–10% FCS. The next morning, the cells were incubated for
25 min at 4
 
8
 
C with Cy5-conjugated anti–HLA-DR (2.06;
American Type Culture Collection) and biotinylated anti-
CD11b (OKM1; American Type Culture Collection) in EDTA-
BSS containing 2% human serum. After two washes, the cells
were incubated with streptavidin–Texas red (Amersham Pharma-
cia Biotech). Mature DCs were then sorted on the basis of
high HLA-DR and negative CD11b fluorescence, together with
characteristic high forward and side light scatter, using a FAC-
Star
 
PLUS™
 
 (Becton Dickinson). Purity was always 
 
.
 
98% after re-
analysis.
 
Stimulation of Human Thymic DCs for IL-12 Production.
 
Iso-
lated thymic DCs (5 or 9 
 
3 
 
10
 
4
 
) were cultured in 96-well round-
bottomed plates in a final volume of 200 
 
m
 
l with human rGM-
CSF (50 ng/ml), human rIFN-
 
g
 
 (20 ng/ml), and CD40L (1 
 
m
 
g/
ml) in the presence or absence of human rIL-4 (20 ng/ml) for 2
or 3 d. The cell-free supernatants were stored until analysis at
 
2
 
70
 
8
 
C.
 
IL-12 Polypeptide Analysis by Western Transfer and Immunoblot-
ting.
 
Aliquots of DC culture supernatants or mouse serum were
subjected to SDS-PAGE (9% acrylamide) under nonreducing
conditions. The electrophoresed proteins were transferred onto
Immobilon-P membrane (Millipore) according to the manufac-
turer’s instructions. Membranes were blocked with 5% BSA in
PBS overnight at 4
 
8
 
C. IL-12 polypeptides were detected by incu-
bation with biotinylated C17.8 (anti–IL-12 p40) mAb (0.5 
 
m
 
g/
ml in 1% BSA, 0.05% Tween 20 in PBS) for 1 h at 4
 
8
 
C, followed
by incubation with streptavidin–horseradish peroxidase conjugate
(Amersham Pharmacia Biotech) dilution in 1% BSA, 0.05%
Tween 20 in PBS for 1 h at 4
 
8
 
C. The membranes were then de-
veloped with Supersignal West Pico Chemiluminescent Substrate
(Pierce Chemical Co.), according to the manufacturer’s instruc-
tions.
 
Analysis of Mouse and Human IL-12 by ELISA.
 
Aliquots of
DC culture supernatants or mouse serum were assayed by two
site ELISA. In brief, 96-well polyvinyl chloride microtiter plates
(Dynatech Laboratories) were coated with the appropriate puri-
fied capture mAb, namely R2-9A5 (anti–mouse IL-12 p70;
 
American Type Culture Collection), 20C2 (anti–human IL-12
p70; BD PharMingen), C15.6 (anti–mouse IL-12 p40; BD
PharMingen), or C8.3 (anti–human IL-12 p40; BD PharMin-
gen). Cytokine binding was then detected with the appropriate
biotinylated detection mAb, namely R1-5D9 (anti–mouse IL-12
p40; American Type Culture Collection), C8.6 (anti–human IL-12
p40; BD PharMingen), or C17.8 (anti–mouse IL-12 p40; hybrid-
oma provided by L. Schofield, The Walter and Eliza Hall Insti-
tute). The readout was then obtained by using streptavidin–
horseradish peroxidase conjugate (Amersham Pharmacia Biotech)
and a substrate solution containing 548 
 
m
 
g/ml 2,2
 
9
 
-azino-bis(3-
ethylbenz-thiazoline-6-sulfonic acid) (ABTS; Sigma-Aldrich) and
0.001% hydrogen peroxide (Ajax Chemicals) in 0.1 M citric acid,
pH 4.2, followed by scanning the optical density at 405–490 nm.
Since the mouse IL-12 p40 ELISA used also detects mouse IL-12
p70, the amount of mouse IL-12 p70 obtained with the mouse
IL-12 p70 ELISA was subtracted from the values obtained with
the mouse IL-12 p40 ELISA.
 
Northern Analysis of IL-12 p40 and p35 mRNA.
 
For North-
ern analysis, groups of three mice were treated with Flt3-L (10
 
m
 
g/d for 10 d) and the splenic DCs were isolated. The adminis-
tration of Flt3-L to C57BL/6 mice greatly enhances the number
of splenic DCs (by 
 
.
 
30-fold), without altering their IL-12 re-
sponse regulation. Cultures of these DCs (13 
 
3
 
 10
 
6
 
 DCs/5 ml
culture) were stimulated for 4 h with CpG (0.5 
 
m
 
M) alone or to-
gether with IFN-
 
g
 
 (20 ng/ml), IL-4 (50 U/ml), or a combina-
tion of the two cytokines. Total RNA isolated from 
 
z
 
2 
 
3
 
 10
 
6
 
DCs using RNAagents (Promega) was fractionated on 1% form-
aldehyde-agarose gels and transferred onto Hybond-C mem-
branes (Amersham Pharmacia Biotech). Filters were baked, pre-
hybridized in 50% formamide, 5
 
3 
 
SSC, 0.02% Ficoll, 0.02%
polyvinylpyrrolidine, 0.02% albumin, and 500 
 
m
 
g/ml of dena-
tured herring sperm DNA, and then hybridized for 18 h at 42
 
8
 
C
with probes at a concentration of 2 
 
3
 
 10
 
6
 
 counts/ml. Filters were
washed in 0.2
 
3
 
 SSC, 0.1% SDS at 65
 
8
 
C, and exposed to autora-
diography at 
 
2
 
70
 
8
 
C. For successive hybridizations, filters were
first treated by boiling in 10 mM EDTA and 0.1% SDS to re-
move bound probe. The probes used were 1-kb EcoRI–HindIII
murine p40 cDNA (36), a 0.66-kb EcoRI–KpnI fragment de-
rived by PCR from the murine p35 cDNA (36), and a 1.1-kb
PstI rat glyceraldehyde 3-phosphate dehydrogenase cDNA (37)
insert. The probes were radiolabeled by random primer extension
with [
 
a
 
-
 
32
 
P]dATP to specific activities ranging between 5 
 
3
 
 10
 
8
 
and 10
 
9
 
 cpm/
 
m
 
g.
 
Results
 
IL-4 Enhancement of Bioactive IL-12 Production by Mouse
Splenic DCs in Response to Microbiological and T Cell–depen-
dent Stimuli. A large number of different stimuli is able to
induce IL-12 production in DCs (4). We analyzed the pro-
duction of IL-12 p70 by freshly isolated mouse spleen DCs
exposed to a panel of stimuli in the presence of GM-CSF
and IFN-g alone or together with IL-4 (Fig. 1). Of the
stimuli tested, LPS and heat-killed SAC are bacteria de-
rived, poly I:C mimics virus-derived double stranded
RNA, and the CpG motif–containing oligodeoxynucle-
otides are a stimulatory component of bacterial DNA.
These can be grouped as stimuli of microbiological origin.
Abs to CD40 or soluble CD40L represent a T cell–derived
stimulus.826 IL-4 Regulates IL-12 Production by Dendritic Cells
Production of the bioactive p70 form of IL-12 required
a microbial or T cell–derived stimulus (Fig. 1). However,
IL-4, in the presence of IFN-g and GM-CSF, enhanced
IL-12 p70 production with all stimuli tested, irrespective of
whether a microbiological or T cell–derived stimulus was
used (Fig. 1 and data not shown). The profound effect of
IL-4 on the production of IL-12 was most clearly seen
when weak IL-12 stimuli were used (LPS, anti-CD40
mAb, poly I:C, or suboptimal doses of CpG); under these
conditions, IL-4 induced up to sixfold more IL-12 p70
production (Fig. 1 and data not shown). In the presence of
potent IL-12 stimuli (SAC, optimal concentration of CpG,
CD40L, or mixes of various stimuli), IL-4 could induce a
further 2.5-fold increase of IL-12 p70 production (Fig. 1,
see Figs. 4 and 5, and data not shown).
Titration of Cytokines Regulating IL-12 Production by Mouse
Splenic DCs. IL-12 production by DCs can be influenced
by several cytokines during the stimulation (4). We ana-
lyzed the influence of IFN-g, GM-CSF, and IL-4 on the
production of the three forms of IL-12. In addition to the
sensitive ELISA assay for the p70 and total p40 production,
we used Western blots to directly visualize the level of the
antagonistic (p40)2 form of IL-12.
Increasing the concentration of IFN- g  during IL-12
stimulation resulted in mouse DCs producing both more
total IL-12 p40 and bioactive IL-12 p70 (Fig. 2, A and B).
However, even maximal concentrations of IFN-g induced
such low levels of bioactive IL-12 p70 that this could only
be detected by sensitive ELISA and not by Western blot.
By contrast, the IFN-g–induced increase in the production
of the antagonistic (p40)2 IL-12 was substantial, detected
by Western blot, and increased in a dose-dependent man-
ner (Fig. 2 C).
The titration of GM-CSF (in the presence of IFN-g) re-
vealed that even relatively small concentrations of GM-
CSF efficiently increased IL-12 p70 production by mouse
DCs (Fig. 3 A). However, the production of IL-12 (p40)2
was only slightly reduced, as was the total IL-12 p40 (Fig.
3, C and B).
The titration of IL-4 (in the presence of IFN-g and
GM-CSF) showed a dose-dependent increase of IL-12 p70
(Fig. 4 A). Moreover, it showed a drastic decrease in total
IL-12 p40, even in the presence of low concentrations of
Figure 1. IL-4 enhances IL-12 p70 production by mouse splenic DCs.
Mouse splenic DCs were cultured with an IL-12 stimulus (LPS, anti-
CD40 mAb, poly I:C, CpG, or SAC [10 mg/ml], or a mix of all stimuli
together) in the presence of GM-CSF and IFN-g with or without IL-4,
for 18 h. The supernatants were assayed for IL-12 p70 content by ELISA.
The result is typical of more than five experiments of this type.
Figure 2. Titration of the effect of IFN-g on the production of IL-12
by mouse splenic DCs. Mouse splenic DCs were cultured with SAC (20
mg/ml) in the presence of titrated concentrations of IFN-g, for 23 h. The
supernatants were analyzed for IL-12 p70 and p40 by ELISA (A and B)
and Western blotting (C). The error bars represent the variation within
one typical experiment. The experiment has been repeated three times
for the ELISA and two times for Western blots, with similar results.827 Hochrein et al.
IL-4 (Fig. 4 B). Importantly, the reduction in total p40 was
associated with a dose-dependent decrease of the antago-
nistic form of IL-12 (p40)2, which was reduced to near un-
detectable levels. The specificity of the effect was substanti-
ated by the addition of an IL-4–neutralizing mAb that
completely blocked the p70 increase and the p40 decrease
induced by IL-4 (Fig. 4).
The Effects of Various Combinations of IL-4, GM-CSF, and
IFN-g on Mouse Splenic DC IL-12 Production. Having de-
termined optimal concentrations, we then analyzed the in-
fluence of IL-4, GM-CSF, and IFN-g, alone or in various
combinations, on the production of the three different
forms of IL-12 by freshly isolated mouse splenic DCs (Fig.
5). An optimal combined stimulus was used with this study,
but similar results were obtained with other strong stimuli
used alone. Similar results were also obtained with splenic
DCs isolated from Flt3-L–treated mice (data not shown).
Without any added cytokine, the stimulus used gave
only marginal production of the bioactive IL-12 p70, but
IL-12 p40 was produced in large excess and some of this
was in the antagonistic homodimeric form (Fig. 5). The
p40/(p40)2 ratio based on densitometry readings was 12.6.
The cytokines were first tested alone. Addition of IL-4
alone increased the amount of IL-12 p70 by .30-fold.
Concomitantly, the amount of total p40 was nearly halved
and Western blot revealed that the remaining p40 was
mainly the monomeric form. The p40/(p40)2 ratio was
then 3,400. GM-CSF, like IL-4, increased the amount of
bioactive IL-12, but had little effect on the total p40. Addi-
tion of IFN-g during the stimulation led to an increase of
all three forms of IL-12, although the increase of the antag-
onistic (p40)2 was most profound. The p40/(p40)2 ratio
Figure 3. Titration of the effect of GM-CSF on the production of
IL-12 by mouse splenic DCs. Mouse splenic DCs were cultured with
SAC (20 mg/ml) in the presence of IFN-g and titrated concentrations of
GM-CSF, for 23 h. The supernatants were analyzed for IL-12 p70 and
p40 by ELISA (A and B) and Western blotting (C). The result is typical of
three experiments with ELISA readouts and Western blotting.
Figure 4. Titration of the effect of IL-4 on the production of IL-12 by
mouse splenic DCs. Mouse splenic DCs were cultured with a mix of
stimuli as used in Fig. 1 (but with SAC used at only 5 mg/ml), in the
presence of IFN-g and GM-CSF and titrated concentrations of IL-4, for
18 h. A neutralizing mAb to IL-4 (10 mg/ml) was included for one set of
conditions as indicated (gray bar). The supernatants were analyzed for IL-
12 p70 and p40 by ELISA (A and B) and Western blotting (C). The re-
sult is typical of three similar experiments with ELISA readouts and
Western blotting.828 IL-4 Regulates IL-12 Production by Dendritic Cells
was then only 2.4. The excess of total p40 over p70 was
z260-fold.
Various combinations of cytokines were then assessed.
The combination of GM-CSF and IL-4, compared with
the individual cytokines alone, resulted in an additive effect
on the production of IL-12 p70 and a reduction of the IL-
12 p40. As with IL-4 alone, no homodimeric p40 was de-
tectable by Western blot. The combination of GM-CSF
and IFN-g resulted in a small increase of p70 compared
with GM-CSF only and a small decrease in total IL-12 p40
compared with IFN-g alone. The combination of IFN-g
and IL-4 had a synergistic effect on the production of IL-12
p70, resulting in 27-fold more IL-12 p70 compared with
IFN-g alone. In contrast, the IFN-g–induced increase of
total IL-12 p40 was much less in the presence of IL-4 (Fig.
5 B). The Western blots showed that some of this reduc-
tion in total p40 was due to a lower production of the
(p40)2 homodimer, the p40/(p40)2 ratio changing from
2.4 to 9.1 (Fig. 5 C). The addition of GM-CSF to the mix
of IFN-g and IL-4 had little effect on p70 production but
led to a further decrease of total IL-12 p40 production as
detected by ELISA. The Western blot revealed an espe-
cially strong decrease in DC production of the antagonistic
(p40)2 homodimer, with a change from a p40/(p40)2 ratio
of 9.1 to a ratio of 161. Thus, the three cytokines used to-
gether gave the best possible agonist to antagonist ratio un-
der the range of conditions tested.
The Independent Regulation of Mouse Spleen DC IL-12 p35
and p40 Gene Expression. The marked changes in the IL-
12 p70 to p40 ratio under the influence of IL-4 suggested
there was independent control of the expression of genes
for IL-12 p35 and IL-12 p40, rather than control of IL-12
being only at the level of the p40 gene. This was tested di-
rectly by Northern analysis of the levels of p35 and p40
mRNA (Fig. 6). To limit the number of mice used, mice
were first pretreated with Flt3-L, which increases DC levels
z30-fold (38). Whereas stimulation of mouse spleen DCs
by CpG alone enhanced mainly the p40 mRNA levels,
stimulation in the presence of IL-4 reduced this p40
mRNA and enhanced markedly the level of p35 mRNA.
Thus, the effects of IL-4 on the p70 to p40 ratio reflected
at least in part, if not entirely, differential regulation of p35
and p40 gene translation.
Regulation of IL-12 Production In Vivo by IL-4. To de-
termine if the effects seen with pure mouse spleen DCs in
culture could occur in vivo, mice were injected with either
LPS or CpG, each either alone or together with IL-4. The
level and form of IL-12 in the serum were tested by ELISA
4 h later (Table I). Both stimuli induced clearly detectable
IL-12 in the serum. With LPS or CpG alone the p40 form
Figure 5. The effects of combinations of IL-4, GM-CSF, and IFN-g
on the IL-12 production by mouse splenic DCs. Mouse splenic DCs were
cultured with a mix of stimuli as used in Fig. 1 in the presence or the ab-
sence of IL-4, IFN-g, or GM-CSF, for 23 h. The supernatants were ana-
lyzed for IL-12 p70 and p40 by ELISA (A and B) and Western blotting
(C). The result is typical of more than five similar experiments with
ELISA readouts and Western blotting.
Figure 6. The effects of IL-4 on p70 expression are mediated by the
regulation of p35 mRNA. Mouse splenic DCs were cultured with CpG
alone or with the addition of IFN-g, IL-4, or both, for 4 h. RNA was
extracted from the cells and subjected to Northern transfer analysis. The
relative amounts of radioactive p35-specific or p40-specific probes bound
to the mRNA samples as quantitated using a PhosphorImager® (Molecu-
lar Probes) are shown. A repeat experiment confirmed these findings.829 Hochrein et al.
predominated. In the presence of IL-4 the ratio of p70/p40
was markedly enhanced, exactly as seen with cultured DCs.
The regulatory system seen in culture appeared to be func-
tional in vivo.
IL-4 Enhancement of Bioactive IL-12 Production by Human
Thymic DCs. The experiments using freshly isolated
mouse DCs demonstrated that IL-4 alone or together with
IFN-g increased the production of IL-12 p70 and simulta-
neously reduced the production of IL-12 p40. It was im-
portant to test if this effect could also be observed with
freshly isolated human DCs or was limited to one species.
Accordingly, we isolated human thymic DCs and stimu-
lated them with CD40L in the presence of GM-CSF and
IFN-g, with or without IL-4. As observed with the mouse
splenic DCs, IL-4 increased IL-12 p70 and decreased IL-12
p40 production in freshly isolated human thymic DCs (Ta-
ble II).
The Effects of IL-4, GM-CSF, and IFN-g on the IL-12
Production by Human Monocyte–derived DCs. Since cul-
tured human MoDCs are the most commonly used DC
preparation due to their ready availability, we checked that
the effects of IL-4, GM-CSF, and IFN-g applied to these
cells as well as to freshly isolated human DCs. This was es-
pecially important in view of the disparate reports of the ef-
fects of IL-4 on monocyte IL-12 production and the possi-
bility that culture of DCs might alter their behavior. These
relatively immature MoDCs expressed intermediate levels
of HLA-DR and HLA-ABC, low levels of CD86, but
no detectable CD80 or CD83; all of these markers could
be upregulated after stimulation with CD40L (data not
shown).
CD40L or a mix of stimuli induced in these MoDCs
only very small amounts of IL-12 p70 but a large excess of
IL-12 p40 if no cytokines were added (Table III). Addition
of IL-4 alone increased the amount of IL-12 p70 in all
three experiments and, concomitantly, reduced IL-12 p40.
GM-CSF alone was less efficient in inducing IL-12 p70
compared with IL-4 and showed little effect on the amount
of the IL-12 p40 produced. IFN-g alone was as good or
better than IL-4 alone in enhancing IL-12 p70, but consis-
tent with the mouse data the amount of IL-12 p40 also in-
creased, resulting in an excess of IL-12 p40 and an IL-12
p40/p70 ratio .300. The combination of IFN-g and IL-4
had a synergistic effect on the production of IL-12 p70, re-
sulting in a 4–17-fold increase of IL-12 p70 compared with
IFN-g alone. Concomitantly, the IFN-g–induced increase
of total IL-12 p40 dropped two- to threefold when com-
bined with IL-4. The combination of IL-4, IFN-g, and
GM-CSF resulted in the optimal ratio of IL-12 p70 to total
p40, in agreement with the results using freshly isolated hu-
man or mouse DCs (Fig. 5).
Discussion
The polarization of T cell cytokine production patterns
into the Th1 and Th2 types has become a basic laboratory
manipulation for cellular immunologists. However, push-
ing the entire T cell immune system to these extremes
would lead to immunopathologies in vivo. It is therefore
likely that regulatory systems exist to maintain a more ap-
propriate, balanced cytokine response in a normal animal.
In this study we describe such a feedback system, mediated,
surprisingly, by IL-4. As well as the well-established posi-
tive feedback by which IL-4, a Th2 cytokine, directly pro-
motes Th2 differentiation from Th0 cells, we have found
that IL-4 also has the potential to promote Th1 differentia-
tion. However, this is an indirect effect, via the action of
IL-4 on DCs to enhance the production and bioactivity of
IL-12, the major Th1-inducing cytokine. This effect of IL-4
on immediate DC IL-12 production is separate from any
effects IL-4 may have in promoting the development of
certain DC populations. This effect on IL-12 production
cannot be considered in isolation, and accordingly, we
have studied the effect of IL-4 in conjunction with other
cytokines and DC stimuli. We have verified that the results
apply to both mouse and human DCs, freshly isolated or
cultured, under a wide range of conditions. We have also
demonstrated that this regulatory system is operative in
vivo. Importantly, we have not just measured the total IL-
Table I. The Influence of IL-4 on the Production of IL-12 p70 
and p40 In Vivo
Stimulus p70 p40
pg/ml ng/ml
None (medium alone) ,60 4 6 1
LPS 127 6 23 162 6 15
LPS 1 IL-4 254 6 73 74 6 4
CpG 693 6 150 369 6 10
CpG 1 IL-4 2,132 6 47 226 6 35
Mice were injected with the stimulus, killed 4 h later, then serum levels
of p40 and p70 IL-12 were determined by ELISA. This experiment was
repeated three times with similar results.
Table II. IL-12 p70 and p40 Production by Isolated Human 
Thymic DCs in the Presence or Absence of IL-4
Experiment
1 p70 (pg/ml) 260 542
p40 (pg/ml) 12,992 5,440
2 p70 (pg/ml) 6 76
p40 (pg/ml) 906 391
IL-4 21
Human thymic DCs (9 3 104 DCs per 200 ml in experiment 1, or 5 3
104 DCs per 200 ml in experiment 2) were incubated with CD40L in
the presence of GM-CSF and IFN-g with or without IL-4 for 3 d
(experiment 1) or 2 d (experiment 2). Supernatants were assayed for IL-
12 p70 and p40 by ELISA.830 IL-4 Regulates IL-12 Production by Dendritic Cells
12 p40, but also monitored the ratio between the bioactive
p70 and the antagonistic (p40)2 IL-12 forms.
IL-4 as the only cytokine, but even more efficiently in
synergy with IFN-g and GM-CSF, increases the IL-12 p70
production of freshly isolated mouse splenic DCs, freshly
isolated human thymic DCs, and cultured human MoDCs.
Concomitantly, it decreases the amount of the total IL-12
p40 and of the antagonistic IL-12 (p40)2. These results
point to an independent regulation of the p40 and p35
components of IL-12. We have confirmed by Northern
analysis that the regulation is at the level of gene transcrip-
tion, and that the p35 and p40 genes are under indepen-
dent control (Fig. 6). The results also suggest a separate reg-
ulation of the formation of the antagonistic homodimer
from the p40 monomer, but we have not examined this in
more detail. It should be emphasized that the cytokines
alone do not provide a sufficient signal for bioactive IL-12
production by DCs, but function together with microbial
or T cell–dependent DC activation stimuli.
These findings are in contrast to some publications re-
porting an inhibitory effect of IL-4 on the ability of DCs to
produce IL-12 p70 (20, 32). One of the studies used an
mAb to CD40, and the other LPS and IFN-g as stimuli. In
our hands, IL-4 clearly enhances IL-12 p70 production of
mouse splenic DCs if the same stimuli or a large panel of
IL-12 stimuli are used (Fig. 1 and data not shown). This ef-
fect of IL-4 is not strain specific, since similar results were
obtained with DCs isolated from BALB/c mice (data not
shown). It also occurs in vivo (Table I). We also found the
same effect with freshly isolated and cultured human DCs.
Clearly, we are dealing with a general phenomenon.
Monocytes can be primed with IL-4 for higher IL-12
production if the cytokine is present at least 1 d before the
contact with a stimulus (26). This effect might reflect the
induction of monocyte differentiation towards a DC phe-
notype. In our studies we can rule out such a priming effect
as the reason for the increase of IL-12 p70 in the presence
of IL-4. First, in the case of the mouse splenic DCs and the
human thymic DCs, we used freshly isolated DCs that al-
ready express surface class II MHC molecules and major
costimulatory molecules (CD40, CD80, and CD86), as
well as in the case of the human thymic DCs, the matura-
tion marker CD83, all at a level typical of mature but not
immature DCs. Second, kinetic studies with mouse splenic
DCs showed that IL-12 production is a very rapid event,
with IL-12 p70 being detected as early as 2 h after stimula-
tion in the presence of IL-4 and reaching a plateau at 10 h
(data not shown).
One reason for the failure to observe these effects of IL-4
previously could be the use of DCs cultured in the pres-
ence of IL-4 and GM-CSF. We have noted that unless
these DCs are washed thoroughly there is sufficient carry-
over of IL-4 and GM-CSF to initiate IL-12 production
without exogenous cytokine addition (data not shown).
This simple technical problem can obscure the difference
between a role of these cytokines in differentiating or
priming the DCs and the role of these same cytokines dur-
ing the actual stimulation of IL-12 production. In addition,
the presence of endotoxin or other microbial products in
antigens or culture media could obscure the requirement
for an additional DC stimulus.
In this study we have used the total DC population,
without separation into the distinct DC subpopulations
(39). One subset, the CD81 mouse spleen DCs, has been
shown to have the highest potential to produce IL-12 in
vitro and in vivo (40–42). We have confirmed that freshly
isolated CD81 DCs are the major IL-12 producers in our
systems and verified that the effects of IL-4 and other cy-
tokines on IL-12 production are also seen with purified
CD81 DCs (data not shown). However, although the ab-
Table III. The Influence of IL-4, IFN-g, and GM-CSF on the Production of IL-12 p70 and p40 of Human MoDCs
Experiment
1 p70 (pg/ml) 0 420 90 430 740 760 4,200 3,920
p40 (ng/ml) 53 20 48 200 21 152 88 75
2 p70 (pg/ml) 40 80 50 330 30 280 1,120 1,250
p40 (ng/ml) 18 12 19 100 11 94 45 42
3 p70 (pg/ml) 9 171 84 1,062 290 3,110 17,100 20,200
p40 (ng/ml) 32 14 33 466 19 553 156 107
IL-4 212 2 1 2 1 1
GM-CSF 221 2 1 1 2 1
IFN-g2 2 2 1 2 1 1 1
Human MoDCs (104 DCs per 200 ml in experiments 1 and 2, 105 DCs per 200 ml in experiment 3) were incubated with CD40L (experiments 1 and
2) or a mix of stimuli containing LPS, poly I:C, CpG, and an mAb for CD40 (experiment 3), and cytokines as indicated for 2 d (experiments 1 and
2) or 1 d (experiment 3). The amount of IL-12 p70 and p40 produced was analyzed by ELISA.831 Hochrein et al.
solute levels of IL-12 are lower, all subtypes of splenic DCs
respond to IL-4 with increased IL-12 p70 and decreased
IL-12 p40 production (data not shown). Furthermore,
since the amounts of IL-12 p70 produced by the CD82
DCs are very low, often under the detection limit without
the addition of IL-4, this leads to the impression that only
CD81 DCs produce IL-12.
Based on our findings, we propose a model integrating
the regulatory effects of IL-4 and IFN-g on the production
of IL-12. DCs receiving appropriate stimuli (either micro-
biological or T cell derived) in a Th2 environment and
thus in the presence of IL-4, will produce IL-12 p70, lead-
ing to IFN-g production by T cells or NK cells. The
strong synergy of IFN-g and IL-4 promotes the production
of high amounts of IL-12 p70, in turn enhancing IFN-g
production. This balances the direct effect of IL-4 in pro-
moting Th2 development. Conversely, an environment
with a high concentration of IFN-g in the absence of IL-4
favors production of the antagonistic IL-12 (p40)2, con-
comitantly counterbalancing any exaggerated Th1 re-
sponse. New primary T cells entering the system, perhaps
responding to different antigens, would therefore be less
likely to be immediately polarized to a Th1 or Th2 cyto-
kine profile. In short, this model provides a mechanism for
the downregulation of a typical Th2 response, mediated via
the major protagonist of Th2 development, IL-4.
In light of a recent finding, a further factor promoting
IL-12 production could be added to this model. IL-4 to-
gether with IL-12 p70 has been shown to induce IFN-g
production by DCs (43). This endogenously produced
IFN-g, together with IL-4, would then amplify the pro-
duction of IL-12 p70, according to our findings. So even in
an extreme Th2 situation, in which the production of T
cell–derived IFN-g is blocked, this production of IFN-g
by DCs could enhance their IL-12 production, which in
turn could induce large amounts of IFN-g from T cells and
NK cells, thus overcoming the Th2 status.
Several findings with animal infection systems strengthen
this model and argue against a general inhibitory role of IL-4
on IL-12 production. In experimental autoimmune uve-
oretinitis in rats, the addition of IL-4 augments the produc-
tion of IFN-g and other Th1-related effector molecules
and aggravates the disease in vivo (44). An additional study
showed that IL-4–deficient mice, in contrast to nondefi-
cient mice, fail to achieve a protective Th1 status in re-
sponse to Candida albicans in the late stage of infection (45).
In addition, our findings and the resulting model fit well
with several observations obtained by Leishmania major in-
fection of mice. Most inbred mouse strains are genetically
resistant, whereas BALB/c mice are susceptible. The sus-
ceptibility of the BALB/c mice is caused by an aberrant
Th2 response to the parasite, in contrast to the protective
Th1 response of resistant strains (46). The critical role of
IL-12 in mounting the protective Th1 response is well es-
tablished, and DCs have been identified as the major
source of IL-12 during L. major infection (47–49). A strain
of mice displaying intermediate susceptibility to L. major
infection develops a dominant Th2 type response during
early weeks of infection, but later switches spontaneously
to Th1 and resolves infection (50). If normally resistant
mice are treated with neutralizing Abs to IL-12 or IFN-g
during the first 3 wk of L. major infection, they develop a
Th2 response and become susceptible. However, during
the Ab treatment they continue to produce IL-12 in spite
of exhibiting a Th2 phenotype, and on discontinuing the
Ab treatment they eventually switch from a Th2 to a Th1
response (51).
The findings presented here have several clinical implica-
tions. Vaccination strategies aimed at producing Th1 re-
sponses must now consider the proinflammatory effects of
IL-4 on DCs as well as the antiinflammatory aspects of IL-4
on the T cells. On the other hand, the knowledge that IL-4
itself has the potential to counterbalance Th2 responses if
DCs and an IL-12 stimulus are present could lead to new
strategies for treating Th2-related diseases, such as allergies
and some parasitic infections. Providing a strong IL-12
stimulus during an ongoing Th2 response might be suffi-
cient to overcome the Th2 bias in some diseases. In fact, it
was recently shown that the addition of a strong IL-12
stimulus (CpG) could reverse an established Th2 response
when given as late as 20 d after lethal L. major infection
(52).
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